Amy S. Clark, MD, MSCE
Medical Oncology
Accepting new patients
Sees patients age 18 and up
Rena Rowan Breast Center
Make an appointmentCall 215-615-5858
Penn Medicine Provider

About me

  • Deputy Director, Breast Cancer Clinical Trials
  • Jill and Alan Miller Associate Professor in Breast Cancer Excellence

Education and training

  • Medical School: Penn State Milton S. Hershey Medical Center
  • Residency: Boston Medical Center
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating

398 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

November 2025
great doctor
November 2025
knowledgeable and relatable
November 2025
very kind and knowledgeable
October 2025
no delay and excellent t service

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Clark is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

DeMichele, A., Clark, A. S., Shea, E., Bayne, E. J., Sterner, C. J., Rohn, K., Dwyer, S., Pan, T., Nivar, I., Chen, Y., Wileyto, P., Berry, L. R., Deluca, S., Savage, J., Makhlin, I., Pant, D. K., Martin, H., Egunsola, A., Mears, N., Goodspeed, B. L., Chislock, E. M., Graves, J., Wang, J., Shih, N., Belka, G. K., Berry, D., Nayak, A., Feldman, M., & Chodosh, L. A. Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial , Nature Medicine : 2025

Clark, A. S., Zhao, F., Klein, P., Montero, A. J., Falkson, C., Krill-Jackson, E., Rowland, K., Sardesai, S., Incorvati, J., Dillon, P., Wolff, A. C., Trauger, R., Heineman, T. C., Coffey, M. C., & Miller, K. D. A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor-Positive Breast Cancer: The BRACELET-01/PrE0113 Study , Clinical cancer research: 2025

Jung W, Hubbard RA, Smith AM, Ko K, Huang A, Wang J, Isaacs JM, Zhang L, Liu PP, Chen Z, Shah PD, Mintzer D, Bhattacharya S, Knollman HM, Clark AS, Koropeckyj-Cox D, Messinger M, Wilcox NS, Xia C, Narayan V, Upshaw JN, Armenian SH, Ky B. Risk-guided cardioprotection with carvedilol in patients with breast cancer (CCT guide): a phase 1 randomized clinical trial. , Breast Cancer Res Treat: 2025

Garrido-Castro, C. A., Gorthi, A., Kim S.E., D'Ippolito, A., Nanda, R., Abdou, Y., Clark, A. S., Sacks, R. L., O'Connor, T. P., Sinclair, N., Lo, K.M.S., Desrosiers, J., Lin, N. U., Burstein, H. J., Mittendorf, E.A., Painter, C., Eaton, M. L., Barrett, C., Tayob, N., Tolaney, S.M. Cell-free circulating chromatin profiles enable epigenomic characterization of mechanisms of response and resistance to sacituzumab govitecan in breast cancer , 2025 ASCO Annual Meeting: 2025

Clark AS, Zhao F, Klein P, Montero AJ, Falkson C, Jackson EK, Rowland K, Sardesai S, Incorvati J, Dillon P, Wolff AC, Trauger R, Heineman TC, Coffey MC, Miller KD BRACELET-01/PrE0113: A Phase II Randomized Study of Paclitaxel (Pac), Pac/Pelareorep (Pel) or Pac/Pel/Avelumab in Metastatic Hormone Receptor Positive Breast Cancer , Clinical Cancer Research : 2025

Gitto, S. B., Pantel, A. R., Maxwell, K. N., Pryma, D. A., Farwell, M. D., Liu, F., Cao, Q., O'Brien, S. R., Clark, A. S., Shah, P. D., & McDonald, E. S. FluorThanatrace PET imaging as a biomarker of response to PARP inhibitors in breast cancer , Communications medicine: 2025

Berlin, E., Ko, K., Ma, L., Messing, I., Hollawell, C., Smith, A. M., Taunk, N. K., Narayan, V., Upshaw, J. N., Clark, A. S., Shah, P. D., Knollman, H., Bhattacharya, S., Koropeckyj-Cox, D., Wang, J., Yegya-Raman, N., Han, I. S., Lefebvre, B., Li, T., Wilcox, N. S., Jung, W., Chen, J., Freedman, G. M., Ky, B. Cardiac Effects of Modern Breast Radiation Therapy in Patients Receiving Systemic Cancer Therapy , JACC. CardioOncology: 2025

Garrido-Castro AC, Kim SE, Desrosiers J, Nanda R, Carey LA, Clark AC, Sacks RL, O’Connor TP, Sinclair NF, Steve Lo KM, Thomas A, Wrabel E, O’Meara T, Lin NU, Burstein HJ, He M, Rimm DL, Mittendorf EA, Tayob N, Tolaney SM Correlation of TROP2 expression with outcomes of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer: an exploratory analysis from the phase II SACI-IO HR+ trial , San Antonio Texas Breast Cancer Symposium, San Antonio, TX : 2024

Garrido-Castro AC, Desrosiers JA, Nanda R, Abdou YG, Clark AS, Sacks RL, O'Connor TP, Sinclair NF, Lo S, Thomas A, Wrabel E, DiLullo MK, Patel A, Rahman T, O'Meara TA, Keenan T, Dillon, DA, Lin NU, Burstein HJ, Mittendorf EA, Junkins KE, Rahee HA Correlation of TROP2 expression with outcomes of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer: an exploratory analysis from the phase II SACI-IO HR+ trial , San Antonio Breast Cancer Symposium, San Antonio, TX: 2024

Linden HM, Ewen D, Mankoff D, Dehdashti F, Fowler AM, Clark AS, Specht JM, Peterson LM [18F]Fluoroestradiol (FES)-PET as a predictive measure for endocrine therapy in patients with newly diagnosed metastatic breast cancer: Results from EAI142 , San Antonio Texas Breast Cancer Symposium, San Antonio, TX: 2024